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In earlier work on  the properdin system only properdin proper was  obtained in 
highly purified form (1), but its role and position in the reaction sequence which leads 
to activation of C3-C9 was not elucidated. Because of the similarity of the C3  acti- 
vator  system  (2)  and  the  properdin  system,  we  investigated  the  possible role  of 
properdin in the activation of  C3  and  C5  via the alternate pathway. In this com- 
munication we wish to report that properdin acts as an essential factor in the early 
reaction steps of the C3 activator system. It appears to function as a modulator which 
enables native C3 to activate C3 proactivator convertase (C3PAse).I 
We  have  previously  shown  that  C3PAse  causes  conversion  of  C3  proactivator 
(C3PA)  to its enzymatically active form, the C3 activator (C3A), and that this en- 
zyme cleaves C3 into C3a and C3b  (2). We also reported that C3PAse acquires en- 
zymatic activity through interaction with C3b and that therefore part of the alternate 
pathway is governed by a positive feedback mechanism (3), a concept recently empha- 
sized by Nicol and Lachmann (4). Consequently, the question arose as to the manner 
in which  C3PAse is switched-on by activators of the  alternate pathway before the 
positive feedback becomes  operative through  production  of  C3b.  Is  properdin  in- 
volved in the initial activation of C3PAse? 
Many similarities between the C3 activator system and the properdin system  (5) 
have become apparent. Isolated C3PA could be equated with Factor B of the proper- 
din system (6, 7). C3, the hydrazine-sensitive factor (HSF) of the C3 activator system 
(3), was found to be the HSF of the properdin system or Factor A  (8, 9). Also, both 
systems were shown to participate in the killing of nonsensitized gram-negative bac- 
teria (1, 2)  and in the lysis of erythrocytes from patients with paroxysmal nocturnal 
hemoglobinuria (10,  11).  Thus,  the earlier findings and  those reported in  this paper 
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appear to establish the identity of the C3 activator system with the properdin system. 
The results have been published in the form of an abstract (12). 
Materials and Methods 
Polysaccharides.--Inulin CP,  purchased  from  Pfanstiehl Laboratories  Inc.  (Waukegan, 
Ill.), was suspended to 50 mg/ml in sterile saline. Zymosan, obtained from Nutritional Bio- 
chemicals Corp. (Cleveland, Ohio), was prepared according to the method described in refer- 
ence 13 and was made up to 50 mg/ml saline. 
Purified Proteins and  Complement Reagents.--Human serum  albumin  (HSA)  was  pur- 
chased from Behringwerke AG  (Marburg,  Germany)  and cytochrome C  from  Calbiochem 
(San Diego, Calif.). Clq (14),  C3  (15),  and cobra venom factor (CVF)  (16) were purified ac- 
cording  to  published methods.  C3b,  the  activated form  of  the  hydrazine-sensitive factor 
(HSFa), was prepared by either of two published methods (3, 17). C3PAse was purified from 
the pseudoglobulin fraction of human ACD-plasma by a  series of column chromatographic 
steps  using  successively  Bio  Rex  70  (Bio-Rad  Laboratories,  Richmond,  Calif.),  carboxy- 
methylcelhilose (Whatman CM-32,  Reeve Angel, Clifton, N.J.),  and Sephadex G75  (Phar- 
macia Fine Chemicals, Piscataway, N.J.). The final product was proved to be homogeneous 
by alkaline gel electrophoresis in 6% polyacrylamide. Details of the purification method will 
be published separately. When necessary, purified components were reconstituted with  re- 
spect to  divalent cations by the  addition  of  0.1  vol  of  a  solution  of  0.01  M  CaCI~-0.02 
M  MgC12 in saline. 
Human  serum  (Shis.)  genetically deficient in  C2  was  kindly provided  by Dr.  Vincent 
Agnello. C3PA-depleted serum was prepared by heating fresh human serum to 50°C  for 30 
min. Human ;serum deficient in C3 was prepared by treatment with hydrazine (3). C3PAse- 
depleted serum was obtained by passage of 20 ml of fresh serum over a 4.5 X  110 cm Sephadex 
G75 column equilibrated in 0.15 M  NaC1, 0.002 M  EDTA, pH 7.3. The bulk of the proteins 
eluting in two peaks was pooled  and concentrated to  the original serum volume.  C3PAse 
elutes after the second protein peak and is thereby separated from all known components of 
complement and the C3  activator system. Human serum specifically depleted  of properdin 
(P)  was obtained using an immune adsorbent prepared from the IgG fraction of a  mono- 
specific rabbit antiserum. This was done as follows: The globulins of 37 ml of antiserum to 
human  P  were  precipitated  at  46%  saturation  of  (NH4)2SO4.  The  precipitated proteins 
were redissolved in and dialyzed against 0.005 M  PO4,  0.002 M  EDTA,  pH 7.3,  containing 
NaC1 to give a conductivity of 4 mmho/cm. A 2.5 X  40 cm column of DE32 cellulose, equil- 
ibrated with the same buffer, was charged with the dialyzed proteins and eluted with the 4 
mmho buffer. The proteins not retained by the column were collected and concentrated to 
15  ml representing a  total of 78 mg of protein. After dialysis against 0.2 M  acetate buffer 
(pH 5.0), 700 mg of HSA was added and both proteins were copolymerized using 0.5 ml of 
ethyl chloroformate (J. T. Baker Chemical Co., PhiUipsburg, N.J.) according to the procedure 
of Avrameas and Ternynck (18). Mter the last wash with phosphate-buffered saline containing 
0.002 M  EDTA,  the immune adsorbent particles were resuspended in fresh human serum 
to which 0.1 vol of 0.2 M  EDTA, pH 7.2, had been added. The mixture was slowly stirred at 
4°C for 1 h. The supernatant serum recovered by high speed centrifugation was frozen im- 
mediately at -70°C in small aliquots. 50 ml of human serum could be depleted of P  by this 
procedure as evidenced by double diffusion in 1% agarose gel by using a  monospecific anti- 
serum to P. Hemolytic titration of the serum before and after adsorption showed a  15% loss 
of CHs0/ml. 
Antisera.--Monospecific antisera to  Clq,  C3,  C3PA,  and P  were  raised in rabbits. The 
first lot of anti-P serum was a gift from Dr. John T. Boyer. It was used to establish the iso- 
lation procedure of P. Later an antiserum to P was prepared in this laboratory and was used 
in all other experiments. Both antisera showed the same specificity for P in human serum as 46  ROLE  OF  PROPERDIN  IN  COMPLEMENT  ACTIVATION 
well as in its isolated form. Rabbit antisera to human IgM, IgG, and IgA, all H-chain specific, 
were purchased from Behringwerke AG. 
Analytical Methods.--Immunoelectrophoresis was performed on microscope slides in 1% 
agarose (Seakem, Marine Colloids, Inc., Springfield, N.J.)  or  1% ion agar no. 2S  (Colab, 
Glenwood, IlL) in veronal buffer, T/2  =  0.05, pH 8.6, containing 0.01 M EDTA. Immuno- 
logical double diffusion was done in 1% agarose in veronal buffered saline, pH 7.4, containing 
0.02 M  EDTA.  Polyacrylamide  electrophoresis was  performed  in 6%  gels in 2-amino-2- 
methyl-l,3-propanediol  (AMPD)  buffer as  described by Tamura and Ui  (19). Gels were 
prepared in AMPD-HC1 buffer, pH 9.5, and the electrode buffer was AMPD-glycine, pH 8.8. 
For sucrose density gradient ultracentrifugation,  the method of Kunkel (20) was followed. 
Gradients were prepared with a Buchler gradient maker, and after application of the samples 
the tubes were centrifuged in a Spinco SW 50 rotor for 16 h at 39,000 rpm (Spinco Division, 
Beckman  Instruments, Inc., Palo  Alto,  Calif.). Protein  was  determined  using  the  Folin 
method (21). 
Hemolysis.--Sensitized sheep erythrocytes  carrying  C4°xY2 or  C4°xy23 were prepared 
and used for effective molecule titrations of  C3  and C5  as  described previously  (22, 23). 
Total hemolytic complement was determined by a standard method (24). 
RESULTS 
Purification of Properdin from Human Serum without the  Use of Zymosan.-- 
Properdin  was  purified from  the  euglobulins precipitated  from  fresh  ACD- 
plasma or serum by dialysis against 0.008 M  EDTA, pH 5.4. The redissolved 
euglobulins were  then successively fractionated on a  2.5  X  40  cm column of 
CM-Sephadex C50,  a  2.5  )< 40 cm column of CM32  cellulose, and a  5  )<  110 
cm  column of  Sepharose  6B  (Pharmacia  Fine  Chemicals).  Column effluents 
were assayed immunochemically  for P. The purification steps are summarized 
in Table I.  Sometimes an  additional passage  over  a  3  >(  115  cm  column of 
Sepharose 6B was necessary to obtain a product of high purity. Large amounts 
of serum (5-7 liter) are required for a  single preparation of purified P  because 
of the low yields which are only 0.5-1% assuming a  P  concentration in serum 
of 25  /~g P/ml (25). Therefore, the euglobulins which are not retained by DE32 
TABLE  I 
Isolation of Properdin (P) from Human Serum 
Precipitation of the euglobulins: 
Chromatography on CM-Sephadex C50: 
Dialysis  of  fresh  serum  against  0.008M 
EDTA, pH 5.4. 
0.02 M  PO4, 0.002 M  EDTA,  pH  6.0. NaC1 
gradient  to  50 mmho. Elution of P: 22-27 
mmho. 
Chromatography on CM-cellulose: 
(CM32) 
0.02 M  PO~, 0.002 M  EDTA,  pH  6.0. NaC1 
gradient to 30 mmho. Elution of P:  11-15 
mmho. 
Chromatography on Sepharose 6B:  0.5 M  NaC1  in  0.05  M  Tris-HC1, 0.002  M 
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cellulose at 0.03  M  PO4, pH 8.1, NaC1 to 4.2 mmho/cm,  a  step which is used 
in the laboratory for the isolation of C3 and C5,  are often combined and used 
as the starting material for P  preparations. The last step of the isolation proce- 
dure,  chromatography on  Sepharose 6B,-often yields two  P-containing peaks 
(Fig.  1).  Since by immunochemical  and activity criteria the properdin in  the 
two peaks appeared to be identical, it is assumed that the earlier eluting peak 
contains  aggregates  of  P  the  size  of  which  was  not  determined.  The  homo- 
geneity of the final product was demonstrated by polyacrylamide electrophore- 
sis (Fig. 2)  and by immunoelectrophoresis (Fig. 3). Purified P  at a  concentra- 
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FIG.  1.  The final step of the isolation of properdin: elution of P from Sepharose 6B. The 
column was continuously monitored at 280 nm for protein. Fractions of 5 ml each were col- 
lected and every second fraction was immunochemicaUy tested for P (bars). 
FIG. 2.  Analysis of isolated P  by polyacrylamide gel electrophoresis,  using  two gel col- 
umns,  one for protein staining and  the other for elution of biologically  and  antigenically 
active material. 160/~g of P were dialyzed against AMPD buffer, pH 9.5, mixed with sucrose 
(10% final concentration)  and 80/zg each were layered on top of the 6% running gels. Another 
6%  running gel was  then polymerized on  top of each liquid sample.  After electrophoresis 
(the anode was at the right) the two segments of one gel were stained, whereas the two seg- 
ments of the second gel were sliced into 2-mm sections as indicated. The sections were eluted 
overnight at 4°C with 0.1  ml of phosphate-buffered  0.3 M  NaCI, pH 7.4, containing 0.1% 
gelatin. The eluates were then assayed for C3 converting activity by incubation with fresh 
serum followed by immunoelectrophoretic  analysis of C3  (top).  P was detected in the same 
eluates by double diffusion in agarose using a monospecific antiserum (bottom). 48  ROLE OF  PROPERDIN IN  COMPLEMENT ACTIVATION 
tion of 0.5 mg/ml did not react with rabbit antisera to human Clq, TgG, IgA, 
or IgM as tested by double diffusion in agarose. Upon sucrose density gradient 
ultracentrifugation, P  from the second peak of the Sepharose 6B column (Fig. 
1)  was found to sediment with an s-rate of 5.4S  (Fig. 4) 
The  Acti~,ity of Isolated Properdin.--When  fresh  normal human serum  or 
human serum genetically deficient in C2  were incubated with isolated P,  the 
conversion of  C3PA  and  of  C3  could readily be  demonstrated by immuno- 
electrophoresis.  In contrast,  C3  and  C3PA  conversion was  observed neither 
when P  was incubated with isolated C3 and/or isolated C3PA, nor when P  was 
added to serum rendered deficient in C3, C3PAse, or C3PA. The deficient sera 
were fully restored with respect to the effect of P  upon addition of the respec- 
FIG. 3.  Immunoelectrophoretic  representation  of  isolated  properdin.  Purified  P  at  a 
concentration of 0.5 mg/ml was analyzed in 1% agarose (upper panel) or 1% ion agar (lower 
panel). For comparison, fresh human serum was included on the slides which were developed 
with a mixture of rabbit anti-P/anti-whole  human serum. As can be seen, agar proved to be 
unsuitable for the detection of P under the conditions used. The anode was at the right. 
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FIG. 4. Analysis of purified P by sucrose density gradient ultracentrifugation. The value 
for P  (5.4S) is an average derived from three separate experiments (5.2S, 5.5S, and 5.6S). 
The position of P in the gradient fractions was determined by its capacity to convert C3 in 
WHS as well as by immunochemical analysis. Both assays located P in the same gradient 
fractions. Markers used were Clq and HSA (llS and 4.5S, both detected immunochemically), 
cytochrome C (1.7S, detected by its adsorbance at 412 nm), and the meniscus (M). OTTO  GOTZEAND  HANS J.  M~LLER-EBERHARD  49 
tive isolated proteins. This is exemplified for  C3PA-deficient sermn in Fig. 5. 
When mixtures containing highly purified P,  C3,  C3PA,  and isolated C3PAse 
were incubated together in the presence of 10  --3 M  magnesium ions, complete 
conversion of  C3  and  nearly  complete  conversion of  C3PA  was  consistently 
demonstrable. Omission of any one of the purified proteins or the addition of 
EDTA prevented both conversion of C3 and of C3PA (Fig. 6). 
Impairment of the C3 Activator System by Specific Depletwn of Serum Proper- 
din.--Fresh serum was depleted of P  by immune adsorption and reconstituted 
with respect to divalent cations. When inulin, one of the known activators of 
the system, was incubated with P-depleted serum,  conversion of C3 could not 
be demonstrated, indicating that P  is essential for the activation of C3 by the 
alternate  pathway.  This  finding  is  consistent  with  the  results  of  the  above 
described experiments in which isolated components had been used. In contrast, 
Fro. 5.  Dependence  of  C3  conversion  by P  on  the presence  of C3PA.  C3PA-depleted 
(heated)  serum was incubated for 30 rain at 37°C with isolated properdin (10 pg/ml serum) 
in the absence and in the presence  of isolated C3PA (100/lg/ml serum).  Two controls,  one 
receiving only C3PA,  the other one only buffer were included.  The mixtures were then as- 
sayed for C3 conversion by immunoelectrophoresis  in 1% ion agar using an antiserum mono- 
specific for C3. The anode was at the right. 
Fro. 6.  Immunoelectrophoretic demonstration of P-induced conversion of isolated C3PA 
and isolated C3. Reaction mixtures (30 ~1) contained: (A) 0.4/~g P, 13/zg C3, 6/zg C3PA, 
and 0.08 gg C3PAse; (B) C3, C3PA, and C3PAse, but no P; (C) P, C3, C3PA, but no C3PAse; 
(D1) P, C3PA, and C3PAse, but no C3; (1)2) P, C3, and C3PAse, but no C3PA. Incubation 
was 30 rain at 37°C. Gels were loaded with 20 pl of the reaction mixtures which were analyzed 
for conversion of C3PA in 1% agarose  (left) and for conversion of C3 in 1% ion agar (right). 
A new anti-C3PA antiserum which detects both fragments of C3PA was used. The anodes 
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FIG.  7.  Conversion of C3 and C3PA in P-depleted serum by various activators.  0.050 ml 
of P-depleted  serum was incubated  for 30 min at 37°C with  1/lg of isolated P, 0.25 mg of 
inulin,  5/zg CVF, or 2  #g HSFa (C3b). Controls received buffer or EDTA (0.002 M  final 
concentration).  Total reaction  volumes were 0.065 ml. Mter incubation  the mixtures were 
analyzed for C3 conversion (left) and for C3PA conversion (right). Slides were stained with 
amido black. The anodes were at the right. 
treatment  of P-depleted serum with isolated P,  CVF, or C3b  (HSFa)  resulted 
in C3 and C3PA conversion (Fig.  7). Heat-aggregated human IgG, an activa- 
tor of the classical pathway, was fully able to trigger C3 conversion in the ab- 
sence of P. 
Consumption of C3 by P in P-Depleted and C2-Deficient Serum.--In order to 
establish  the quantitative  relationship  between  the degree of activation of C3 
and  the  amount  of P  required,  experiments  were  performed in  which  graded 
amounts  of isolated  P  were  incubated  with  P-depleted  serum  for 30  rain  at 
37°C. The consumption of hemolytically active  C3  by each  amount of P  was 
then  determined  with  EAC4°xy2 cells.  A  linear  relationship  was observed  be- 
tween  C3H50  consumption  and  the  input  of P  when  plotted  in  terms  of y/ 
(1  -  y) vs./zg properdin.  When the data were expressed in percent consump- 
tion of effective  C3  molecules,  as  shown in  Fig. 8,  C3  consumption increased 
with increasing  amounts of P.  The highest amount of P  used  (1.5 #g/0.05  ml 
of P-depleted serum) is similar to that reported to occur in whole human serum 
(25). Several different activators of the alternate pathway were compared with 
regard  to  their  effects in  C2-deficient  and  P-depleted  serum.  The  results  are 
given in Table II. 
Consumption of C5 by P in P-Depleted Serum.--Early during  our investiga- 
tion it had been observed that P,  although efficient in activating C3, initiated 
consumption of C5  in normal human  serum only to a  very small  extent  (ap- 
proximately  10 %).  Experiments dealing with  the activation of C5 were there- 
fore repeated  and  extended  using  P-depleted  serum.  It  was found that  there OTTO  GOTZE  AND  HANS  J.  ~IOLLER-EBERHARD  51 
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FIG. 8.  Quantitative relation between C3 consumption  in P-depleted serum and amount 
of added purified P. Increasing amounts of purified P were added to 0.050 ml of P-depleted 
serum and were incubated for 30 rain at 37°C in a total reaction volume of 0.080 ml. C3 con- 
sumption was then determined by effective molecule titration. 
TABLE II 
Consumption of C3 in Properdin (P)-Depleted and in C2-Deficient Serum 
Serum  Activator  Concentration  Consumption of C3" 
Properdin-depleted 
mg/mt  % 
P  0.08  94.9 
CVF  0.16  94.0 
Inulin  5.00  10.1 
P plus  0.08  100.0 
Inulin  5.00 
C3b  0.40  43.0 
C2-deficient  P  0.06  43.7 
P plus  0.06  64.5 
Inulin  5.00 
Inulin  5.00  27.0 
* Measured as effective molecules. 
was little C5  consumption except with the highest amounts  of P  used  (about 
15 %  consumption with 1.5/zg P/0.05  ml serum). If, however, the reaction was 
performed  in  the  presence  of  0.25  mg  zymosan,  effident  consumption  of  C5 
was demonstrable, reaching about 40 %  at less than 0.04/zg P/0.05  ml serum. 
Incubation  of larger amounts  of P  in  the  presence  of zymosan  resulted in  a 
marked inhibition of this consumption (Fig. 9). 
DISCUSSION 
The  present studies were initiated in order to  evaluate the possible role of 
properdin in  the  C3  activator system  and  thereby to  clarify the  relationship 52  ROLE  OF  PROPERDIN  IN  COMPLEMENT  ACTIVATION 
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FzG. 9.  Quantitative  relation between C5 consumption in P-depleted serum and amount 
of added purified P in the presence and absence of zymosan. Increasing amounts of purified 
P were added to P-depleted serum in the absence or the presence of 0.25 mg of zymosan and 
were incubated for 30 rain at 37°C in a total reaction volume of 0.080 ml. C5 consumption 
was then  determined by effective molecule titration.  The values obtained  by incubation 
with P  and zymosan were corrected for the amount of C5  consumed by incubation with 
zymosan alone which was between 8-12%. 
of this system to the properdin system. Because it was thought probable that 
P  purified by adsorption  to zymosan according to Pensky et at.  (1)  might be 
in  an altered state,  a  purification procedure based on conventional chromato- 
graphic methods was designed.  Using this procedure highly purified properdin 
was  obtained  which  showed  molecular  homogeneity  upon  physicochemical 
and immunochemical analysis. Properdin is a highly basic plasma protein which 
exhibits  a  net  positive  charge  during  polyacrylamide  electrophoresis  at  pH 
9.5. Its s-rate upon sucrose density gradient ultracentrifugation  was found to 
be 5.4S. These results are in agreement with those published in 1968 for zymo- 
san purified P  by Pensky et  at.  (1)  who found  a  sedimentation  coefficient of 
5.2-6.4S  and  a  molecular  weight  of  223,000  daltons.  Recently,  Minta  and 
Lepow  (26)  reported  a  molecular  weight  of  184,000  daltons  for  zymosan- 
purified properdin. The protein was found to be composed of four noncovalently 
linked subunits of 45,000  daltons each. In our experiments, P  eluted from gel 
permeation chromatography columns with an elution volume between that of 
Clq and IgG. All those data are suggestive of a molecule with a high frictional 
ratio.  Properdin  apparently has  a  propensity to  form aggregates  (Fig.  1),  a 
behavior  which  might  explain  the  higher  sedimentation  coefficients  (from 
10S  to 27S)  which have been reported in the earlier literature  (5,  27-29). 
All  P  preparations obtained by the  described  method  caused immunoelec- 
trophoretic conversion of C3PA and of C3 as well as consumption of hemolyti- 
cally active C3  when incubated  with fresh serum or P-depleted serum in  the 
absence of activating substances such as inulin.  In order to evaluate the pre- 
cise requirements for these reactions, several experiments using isolated, highly OTTO  GOTZE AND  HANS  J.  MULLER-EBERHARD  53 
purified components were performed. In view of the known role of C3b as an 
activator of C3PAse,  special care was exercised to utilize only those protein 
preparations which were entirely devoid of C3b. It was found that C3PA con- 
version  occurred in  the  isolated  system  only when  properdin,  C3,  C3PAse, 
and magnesium ions were present. Similarly, C3 conversion required P, C3PAse, 
C3PA,  and magnesium ions (Fig. 6). Inulin could not replace P  in these reac- 
tions. 
It is conceivable that the observed effects of P  in fresh serum as well as in 
the isolated system are, at least in part, due to contamination of the isolated 
protein with endotoxins which  are known  to be potent  activators of the  C3 
activator system. The results of sucrose density gradient ultracentrifugation 
seem to argue against this possibility, since both the P  antigen as well as the 
P  activity were found to sediment congruently with 5.4S, whereas contaminat- 
ing endotoxins would be expected to sediment at a faster rate. 
An  absolute requirement for P  in  the alternate pathway could be demon- 
strated with the use of specifically P-depleted serum. Whereas activators which 
interact  directly with  C3PA  or  C3PAse,  such  as  CVF  and  C3b,  were  still 
able to initiate C3 conversion, inulin was virtually unable to trigger the system 
in the absence of P  (Fig. 7). 
These results show that two groups of activating substances of the alternate 
pathway may be distinguished. One group of substances is capable of acting 
independent  of  P  (CVF  and  C3b).  Other  activators  such  as  inulin  require 
participation of P. This applies probably also to other polysaccharides, endo- 
toxins, IgA aggregates (30, 31), and the nephritic factor (32). Results pertain- 
ing to some of these aspects were also presented by others (33, 34). The results 
further show that  the isolated properdin was  obtained in  an  activated state 
from a precursor and that it differs functionally from the form in which it exists 
in  plasma  or  fresh  serum.  Precursor  properdin  can  become  activated  after 
addition of substances such as inulin, zymosan, endotoxins, or IgA aggregates 
to  serum,  either  by  direct interaction  or  by mediation  of  additional  serum 
factors.  The  latter  possibility  has  been  raised  by  Spitzer  and  Stitzel  (35). 
Since there is as yet no evidence that activated P  (P)  can cleave C3  directly 
to generate C3b which is known to activate C3PAse,  it is postulated that P 
interacts with native C3 in a way which causes expression of C3PAse activity. 
This  enzyme wou!d then  activate  C3PA  which  in  turn  cleaves  C3,  thereby 
initiating the C3b-dependent positive feedback mechanism of the C3 activator 
system (3). Our concept of these reactions is schematically depicted in Fig. 10. 
Purified  P  efficiently triggers  the  activation  or  consumption  of  C3  in  P- 
depleted or fresh serum in the absence of particulate polysaccharides. C5  acti- 
vation by P,  however, is  not efficiently initiated  in  the  absence of inulin  or 
zymosan and is markedly inhibited at higher P  concentrations when zymosan 
is present (Fig. 9). The effect of insoluble polysaccharide on the formation of a 
P-dependent C5 convertase might be due to a stabilization of molecular interac- 54  ROLE  OF  PROPER.DIN  IN  COMPLEMENT  ACTIVATION 
Activating 
Substance 
I 
I 
I 
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C3a  C3b  A  ~  C3b[ 
Fragment  C3A-  -  C3blNA 
C3 
FIG. 10. Present concept of the molecular  mechanisms of the alternate pathway of com- 
plement activation. 
tions between several proteins through binding to a  surface. Inhibition of the 
C5 convertase by larger amounts of P  might be explained on the basis of steric 
hindrance at the site of assembly of this multicomponent enzyme. 
The present study assigns to P  an essential role during the early reactions 
leading  to  the  activation of  C3-C9  via  the  alternate  pathway.  It  does not, 
however, exclude the possibility that P  is  also required for the formation of 
the C5 convertase and that it might be an integral part of this complex enzyme. 
SI.rMMAR¥ 
Properdin  (P),  a  highly basic  euglobulin,  was  purified from human  serum 
to molecular homogeneity without the use of zymosan. Isolated P  was found 
to efficiently initiate activation of the  alternate pathway of complement ac- 
tivation (C3 activator or properdin system) and to be an essential component 
during its early reaction stages. The activity of isolated P  did not require the 
presence  of  an  activating  polysaccharide.  It  was  therefore  concluded  that 
purified P  had been obtained in an activated form (P). 
In  an  isolated  reaction  system  containing  purified  C3,  C3  proactivator 
(C3PA), and C3 proactivator convertase (C3PAse), P  was able to mediate the 
activation of C3PAse which in turn activated C3PA to cleave C3. This activa- 
tion of C3PAse was found to depend on the presence of native C3. These re- 
sults allowed the formulation of a concept in which P  is envisaged to act as a 
modulator of native C3 enabling it to activate C3PAse. 
Activation of C3 was efficiently mediated by F  in the fluid phase. Efficient 
activation  of  C5,  however,  required  the  participation  of  an  insoluble  poly- 
saccharide (zymosan). The possibility is raised therefore that P  might also be 
an integral part of the mulfimolecular C5 convertase of the alternate pathway 
of complement activation. OTTO GOTZE AND HANS J. Mt~LLER-EBERHARD  55 
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